Presentation is loading. Please wait.

Presentation is loading. Please wait.

Late Stage Chronic Kidney Disease Drugs Market Forecast

Similar presentations


Presentation on theme: "Late Stage Chronic Kidney Disease Drugs Market Forecast"— Presentation transcript:

1 Late Stage Chronic Kidney Disease Drugs Market Forecast
to 2028 Published Date : Nov 2022

2 Report Studies Late Stage Chronic Kidney Disease Drugs Market Forecast to COVID- 19 Impact and Global Analysis by Product Type (Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Others); Indication (Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalaemia); Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and Geography

3 Late Stage Chronic Kidney Disease Drugs Market Valuation
Late Stage Chronic Kidney Disease Drugs Market Valuation $50,000 $40,000 $30,000 CAGR of 11.6 % $20,000 ( ) $10,000 $0 20XX 20XX 20XX 20XX 20XX

4 Late Stage Chronic Kidney Disease Drugs Market Overview
Late Stage Chronic Kidney Disease Drugs Market Overview The late stage chronic kidney disease drugs market was valued at US$ 4, million in 2019 and is projected to reach US$ 11,096.9 million by 2027; it is expected to grow at a CAGR of 11.6% from 2020 to 2027. The market growth is also attributed to a few key factors such as high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs. However, delay in the diagnosis of chronic kidney disease is expected to hamper the growth of the market up to certain extent during the forecast period.

5 Key Segment Market Download Sample Here Segment By Type:-
Key Segment Market Segment By Type:- By Product Type (Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Others) Indication (Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalaemia) Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and Geography Download Sample Here

6 Company Profiles Download Sample Here
Company Profiles Takeda Pharmaceutical Company Limited Astellas Pharma Inc. Bayer AG Vifor Pharma Management Ltd. Akebia Drugs, Inc. AbbVie Inc. Amgen AstraZeneca Sanofi Kyowa Kirin Co., Ltd. Download Sample Here

7 By Geography Download Sample Here
By Geography North America (the US, Canada, and Mexico) Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe) Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific) Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa) South & Central America (Brazil, Argentina, and the Rest of South & Central America). Download Sample Here 7

8 THANK YOU! E-Mail : sales@theinsightpartners.com
Phone :


Download ppt "Late Stage Chronic Kidney Disease Drugs Market Forecast"

Similar presentations


Ads by Google